ResMed, Inspire Medical Drop After Lilly’s Zepbound Study
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
- Latest
- Trending
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.